U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H19FN4O3
Molecular Weight 370.3776
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BRIVANIB

SMILES

C[C@@H](O)COC1=CN2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1C

InChI

InChIKey=WCWUXEGQKLTGDX-LLVKDONJSA-N
InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H19FN4O3
Molecular Weight 370.3776
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created using several sources including: https://www.ncbi.nlm.nih.gov/pubmed/16570908 | https://www.ncbi.nlm.nih.gov/pubmed/18829493 | https://www.ncbi.nlm.nih.gov/pubmed/21349999 | https://www.ncbi.nlm.nih.gov/pubmed/22238246 | http://www.hrsa.gov/opa/programrequirements/orphandrugexclusion/orphandruglistarchived.pdf

Brivanib is a pyrrolotriazine-based compound and an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antineoplastic activity. It specifically targets and strongly binds to human VEGFR-2, a tyrosine kinase receptor and pro-angiogenic growth factor expressed almost exclusively on vascular endothelial cells. Blockade of VEGFR-2 by this agent may lead to an inhibition of VEGF-stimulated endothelial cell migration and proliferation, thereby inhibiting tumor angiogenesis. Brivanib has a moderate potency compared to VEGFR-2 against VEGFR-1 and FGFR-1 as well. Brivanib is suggested to be efficient in treatment of hepatocellular carcinoma (HCC). As first-line and as second-line therapy brivanib demonstrated promising antitumor activity and a manageable safety profile in patients with advanced, unresectable HCC in phase II clinical trials. On 3 march 2011, orphan designation was granted by the European Commission to Bristol-Myers Squibb for brivanib alaninate for the treatment of hepatocellular carcinoma.[

Originator

Curator's Comment: # Bristol-Myers Squibb

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.0 nM [Kd]
1039.0 nM [Kd]
1892.0 nM [Kd]
Target ID: P35968
Gene ID: 3791.0
Gene Symbol: KDR
Target Organism: Homo sapiens (Human)
25.0 nM [IC50]
Target ID: P17948|||B3FR89
Gene ID: 2321.0
Gene Symbol: FLT1
Target Organism: Homo sapiens (Human)
0.38 µM [IC50]
Target ID: P11362|||Q14307|||Q9UDF2
Gene ID: 2260.0
Gene Symbol: FGFR1
Target Organism: Homo sapiens (Human)
0.148 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6610 ng/mL
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVANIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2847 ng/mL
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVANIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
62813 ng × h/mL
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVANIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
53685 ng × h/mL
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVANIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.3 h
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVANIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
18.3 h
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BRIVANIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1000 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources: Page: p.1415
DLT: Mental status changes, Fatigue...
Other AEs: Arterial hypertension...
Dose limiting toxicities:
Mental status changes (grade 3, 25%)
Fatigue (grade 3, 25%)
Other AEs:
Arterial hypertension (grade 3-4, 25%)
Sources: Page: p.1415
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 20
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 20
Sources: Page: p.1415
Other AEs: Dizziness, ALT increased...
Other AEs:
Dizziness (grade 3-4, 5%)
ALT increased (grade 3-4, 15%)
AST increased (grade 3-4, 5%)
Fatigue (grade 3-4, 15%)
Arterial hypertension (grade 3-4, 15%)
Diarrhea (grade 3-4, 10%)
Sources: Page: p.1415
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Disc. AE: Cardio-respiratory arrest, Cerebral infarction...
AEs leading to
discontinuation/dose reduction:
Cardio-respiratory arrest (grade 5, 0.17%)
Cerebral infarction (grade 5, 0.17%)
Hepatic failure (grade 5, 0.17%)
Diarrhea (grade 5, 0.17%)
Upper gastrointestinal hemorrhage (grade 5, 0.17%)
Asthenia (grade 5, 0.17%)
Cerebrovascular accident (grade 5, 0.17%)
Hematemesis (grade 5, 0.17%)
Gastrointestinal hemorrhage (grade 5, 0.17%)
Skin disorder (2%)
Fatigue (5%)
Hyponatremia (2%)
Decreased appetite (2%)
Hyperbilirubinemia (2%)
Skin disorder (3%)
AST increased (2%)
Sources: Page: p.3520-3522
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.137
unhealthy, ADULT
n = 595
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 595
Sources: Page: p.137
Disc. AE: Dyspnoea, Cerebral haemorrhage...
AEs leading to
discontinuation/dose reduction:
Dyspnoea (1.8%)
Cerebral haemorrhage (grade 5, 0.17%)
Intracranial haemorrhage (grade 5, 0.17%)
Hypovolemic shock (grade 5, 0.17%)
Multi-organ failure (grade 5, 0.17%)
Bowel perforation (grade 5, 0.17%)
Pulmonary haemorrhage (grade 5, 0.17%)
Vomiting (1.8%)
Sources: Page: p.137
AEs

AEs

AESignificanceDosePopulation
Fatigue grade 3, 25%
DLT
1000 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources: Page: p.1415
Mental status changes grade 3, 25%
DLT
1000 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources: Page: p.1415
Arterial hypertension grade 3-4, 25%
1000 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 4
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 4
Sources: Page: p.1415
Diarrhea grade 3-4, 10%
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 20
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 20
Sources: Page: p.1415
ALT increased grade 3-4, 15%
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 20
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 20
Sources: Page: p.1415
Arterial hypertension grade 3-4, 15%
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 20
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 20
Sources: Page: p.1415
Fatigue grade 3-4, 15%
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 20
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 20
Sources: Page: p.1415
AST increased grade 3-4, 5%
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 20
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 20
Sources: Page: p.1415
Dizziness grade 3-4, 5%
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1415
unhealthy, ADULT
n = 20
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 20
Sources: Page: p.1415
AST increased 2%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Decreased appetite 2%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Hyperbilirubinemia 2%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Hyponatremia 2%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Skin disorder 2%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Skin disorder 3%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Fatigue 5%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Asthenia grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Cardio-respiratory arrest grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Cerebral infarction grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Cerebrovascular accident grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Diarrhea grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Gastrointestinal hemorrhage grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Hematemesis grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Hepatic failure grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Upper gastrointestinal hemorrhage grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.3520-3522
unhealthy, ADULT
n = 575
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 575
Sources: Page: p.3520-3522
Dyspnoea 1.8%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.137
unhealthy, ADULT
n = 595
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 595
Sources: Page: p.137
Vomiting 1.8%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.137
unhealthy, ADULT
n = 595
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 595
Sources: Page: p.137
Bowel perforation grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.137
unhealthy, ADULT
n = 595
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 595
Sources: Page: p.137
Cerebral haemorrhage grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.137
unhealthy, ADULT
n = 595
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 595
Sources: Page: p.137
Hypovolemic shock grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.137
unhealthy, ADULT
n = 595
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 595
Sources: Page: p.137
Intracranial haemorrhage grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.137
unhealthy, ADULT
n = 595
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 595
Sources: Page: p.137
Multi-organ failure grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.137
unhealthy, ADULT
n = 595
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 595
Sources: Page: p.137
Pulmonary haemorrhage grade 5, 0.17%
Disc. AE
800 mg 1 times / day multiple, oral
MTD
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.137
unhealthy, ADULT
n = 595
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 595
Sources: Page: p.137
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
likely
minor [IC50 44.5 uM]
moderate [IC50 18.4 uM]
moderate [IC50 26.2 uM]
moderate [IC50 34.7 uM]
no
weak
weak
weak
yes [IC50 1.39 uM]
yes [IC50 25.3 uM]
yes [IC50 3.08 uM]
yes [IC50 3.64 uM]
yes [IC50 5.95 uM]
yes [IC50 6.98 uM]
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major [Km 32.7 uM]
major [Km 45 uM]
minor
minor
minor
minor
minor
minor
minor
minor
minor
no
no
no
yes
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
2006 Apr 6
By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy.
2008
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
Patents

Sample Use Guides

800 mg brivanib once daily until disease progression or toxicity treatment for liver cancer in Asian patients who have failed or could not tolerate sorafenib therapy
Route of Administration: Oral
The SK-HEP1 and HepG2 cells were used to investigate the effects of brivanib on the VEGFR-2 and FGFR-1 signaling pathways in vitro.To study the effects of brivanib treatment on VEGF- and bFGF-stimulated activation of Akt and ERK1/2 pathways, SK-HEP1 and HepG2 cells were treated with 2 uM brivanib for 24 h and then stimulated with 40 ng/mL VEGF or bFGF. In addition, brivanib SK-HEP1 cells were also stimulated with IGF-1 for 15 min. The cells were lysed and the lysates were analyzed for levels of the effector proteins, including the serine/threonine kinase Akt and ERK1/2.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:15:22 GMT 2023
Edited
by admin
on Fri Dec 15 16:15:22 GMT 2023
Record UNII
DDU33B674I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BRIVANIB
MI   USAN   WHO-DD  
USAN  
Official Name English
BRIVANIB [USAN]
Common Name English
BMS-540215
Code English
2-PROPANOL, 1-((4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-5-METHYLPYRROLO(2,1-F)(1,2,4)TRIAZIN-6-YL)OXY)-, (2R)-
Systematic Name English
Brivanib [WHO-DD]
Common Name English
BRIVANIB [MI]
Common Name English
(2R)-1-({4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1967
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
NCI_THESAURUS C1742
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C67040
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
PUBCHEM
11234052
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
ChEMBL
CHEMBL377300
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
MERCK INDEX
m2653
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY Merck Index
MESH
C509922
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
EPA CompTox
DTXSID60215294
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
CHEBI
167686
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
FDA UNII
DDU33B674I
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
SMS_ID
100000127529
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
DRUG BANK
DB11958
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
USAN
WW-39
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
EVMPD
SUB33565
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
CAS
649735-46-6
Created by admin on Fri Dec 15 16:15:22 GMT 2023 , Edited by admin on Fri Dec 15 16:15:22 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
PLASMA
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION